| Identification | Back Directory | [Name]
Sovilnesib | [CAS]
2410796-79-9 | [Synonyms]
AMG-650
Sovilnesib
AMG 650（Sovilnesib）
Sovilnesib (Synonyms: AMG 650)
Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[(2-hydroxyethyl)sulfonyl]amino]- | [Molecular Formula]
C26H34F2N6O4S | [MOL File]
2410796-79-9.mol | [Molecular Weight]
564.65 |
| Chemical Properties | Back Directory | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
7.48±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
KBDGEJDIHZDPHN-UHFFFAOYSA-N | [SMILES]
C(NC1C=C(C)N=C(N2CCC(F)(F)CC2)N=1)(=O)C1=CC=C(NS(CCO)(=O)=O)C=C1N1CCC2(CC2)CC1 |
| Hazard Information | Back Directory | [Description]
Sovilnesib (AMG 650) is a kinesin-like protein KIF18A inhibitor (WO2020132648). Sovilnesib can be used for the research of cancer. | [in vitro]
Sovilnesib is a kinesin-like protein KIF18A inhibitor. | [in vivo]
Sovilnesib (AMG 650; 10-100 mg/kg; p.o. daily, for 45 d; female nude mice without thymus with OVCAR-3 xenografts) inhibits tumor growth, Lasting tumor regression and cure occurred in 50% of the animals, Sovilnesib has no apparent toxicity.
| [Clinical claims and research]
Sovilnesib (AMG-650) is under development for the treatment of triple-negative breast cancer (TNBC), platinum-resistant high grade serous ovarian cancer, primary peritoneal cancer, fallopian tube cancer, serous endometrial cancer and other solid tumors with TP53 gene mutation (TP53MUT). The drug candidate is administered orally as tablet. It acts by targeting KIF18A.
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
|